• Something wrong with this record ?

Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia

N. Gökbuget, H. Dombret, S. Giebel, M. Bruggemann, M. Doubek, R. Foà, D. Hoelzer, C. Kim, G. Martinelli, E. Parovichnikova, A. Rambaldi, JM. Ribera, M. Schoonen, JM. Stieglmaier, G. Zugmaier, R. Bassan,

. 2019 ; 24 (1) : 337-348.

Language English Country England, Great Britain

Document type Clinical Trial, Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc19011926

OBJECTIVES: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. This study evaluated outcomes of patients with B-cell precursor ALL with MRD of ≥10-4 Methods: Study population was from ALL study groups in Europe managed in national study protocols 2000-2014. MRD was measured by polymerase chain reaction or flow cytometry. Patients were age ≥15 years at initial ALL diagnosis. Patients were excluded if exposed to blinatumomab within 18 months of baseline or prior alloHSCT. RESULTS: Of 272 patients in CR1, baseline MRD was ≥10-1, 10-2 to <10-1, 10-3 to <10-2, and 10-4 to <10-3 in 15 (6%), 71 (26%), 109 (40%), and 77 (28%) patients, respectively. Median duration of complete remission (DoR) was 18.5 months (95% confidence interval [CI], 11.9-27.2), median relapse-free survival (RFS) was 12.4 months (95% CI, 10.0-19.0) and median overall survival (OS) was 32.5 months (95% CI, 23.6-48.0). Lower baseline MRD level (P ≤ .0003) and white blood cell count <30,000/μL at diagnosis (P ≤ .0053) were strong predictors for better RFS and DoR. Allogeneic hematopoietic stem cell transplantation (alloHSCT) was associated with longer RFS (hazard ratio [HR], 0.59; 95% CI, 0.41-0.84) and DoR (HR, 0.43; 95% CI, 0.29-0.64); the association with OS was not significant (HR, 0.72; 95% CI, 0.50-1.05). DISCUSSION: In conclusion, RFS, DoR, and OS are relatively short in patients with MRD-positive ALL, particularly at higher MRD levels. AlloHSCT may improve survival but has limitations. Alternative approaches are needed to improve outcomes in MRD-positive ALL.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19011926
003      
CZ-PrNML
005      
20240516121931.0
007      
ta
008      
190405s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/16078454.2019.1567654 $2 doi
035    __
$a (PubMed)30757960
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Gökbuget, Nicola $u Department of Medicine II, Department of Hematology/Oncology , University Hospital , Frankfurt , Germany.
245    10
$a Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia / $c N. Gökbuget, H. Dombret, S. Giebel, M. Bruggemann, M. Doubek, R. Foà, D. Hoelzer, C. Kim, G. Martinelli, E. Parovichnikova, A. Rambaldi, JM. Ribera, M. Schoonen, JM. Stieglmaier, G. Zugmaier, R. Bassan,
520    9_
$a OBJECTIVES: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. This study evaluated outcomes of patients with B-cell precursor ALL with MRD of ≥10-4 Methods: Study population was from ALL study groups in Europe managed in national study protocols 2000-2014. MRD was measured by polymerase chain reaction or flow cytometry. Patients were age ≥15 years at initial ALL diagnosis. Patients were excluded if exposed to blinatumomab within 18 months of baseline or prior alloHSCT. RESULTS: Of 272 patients in CR1, baseline MRD was ≥10-1, 10-2 to <10-1, 10-3 to <10-2, and 10-4 to <10-3 in 15 (6%), 71 (26%), 109 (40%), and 77 (28%) patients, respectively. Median duration of complete remission (DoR) was 18.5 months (95% confidence interval [CI], 11.9-27.2), median relapse-free survival (RFS) was 12.4 months (95% CI, 10.0-19.0) and median overall survival (OS) was 32.5 months (95% CI, 23.6-48.0). Lower baseline MRD level (P ≤ .0003) and white blood cell count <30,000/μL at diagnosis (P ≤ .0053) were strong predictors for better RFS and DoR. Allogeneic hematopoietic stem cell transplantation (alloHSCT) was associated with longer RFS (hazard ratio [HR], 0.59; 95% CI, 0.41-0.84) and DoR (HR, 0.43; 95% CI, 0.29-0.64); the association with OS was not significant (HR, 0.72; 95% CI, 0.50-1.05). DISCUSSION: In conclusion, RFS, DoR, and OS are relatively short in patients with MRD-positive ALL, particularly at higher MRD levels. AlloHSCT may improve survival but has limitations. Alternative approaches are needed to improve outcomes in MRD-positive ALL.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a alografty $7 D064591
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    12
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a filadelfský chromozom $7 D010677
650    12
$a pre-B-buněčná leukemie $x krev $x mortalita $x terapie $7 D015452
650    _2
$a míra přežití $7 D015996
651    _2
$a Evropa $7 D005060
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Dombret, Hervé $u Hôpital Saint-Louis, University Paris Diderot , Paris , France. $7 xx0316388
700    1_
$a Giebel, Sebastian $u Maria Sklodowska Curie Memorial Cancer Center , Gliwice , Poland.
700    1_
$a Bruggemann, Monika $u Department of Hematology and Oncology , University Hospital Schleswig-Holstein, Campus Kiel , Kiel , Germany.
700    1_
$a Doubek, Michael $u Department of Internal Medicine, Hematology and Oncology , University Hospital , Brno , Czech Republic.
700    1_
$a Foa, Robin $u "Sapienza" University of Rome , Rome , Italy. $7 xx0317383
700    1_
$a Hoelzer, Dieter $u Department of Medicine II, Department of Hematology/Oncology , University Hospital , Frankfurt , Germany.
700    1_
$a Kim, Christopher $u Amgen Inc , Thousand Oaks , CA , USA.
700    1_
$a Martinelli, Giovanni $u Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS , Meldola , Italy.
700    1_
$a Parovichnikova, Elena $u National Research Center for Hematology , Moscow , Russia.
700    1_
$a Rambaldi, Alessandro $u Dipartimento di Oncologia ed Ematologia , Università degli Studi di Milano and Ospedale Papa Giovanni XXIII , Bergamo, Italy. $7 xx0317376
700    1_
$a Ribera, Josep-Maria $u ICO-Hospital Germans Trias I Pujol, Josep Carreras Research Institute , Barcelona , Spain.
700    1_
$a Schoonen, Marieke $u Amgen Ltd , London , UK.
700    1_
$a Stieglmaier, Julia M $u Amgen GmBH , Munich , Germany.
700    1_
$a Zugmaier, Gerhard $u Amgen GmBH , Munich , Germany.
700    1_
$a Bassan, Renato $u Ospedale dell'Angelo , Mestre-Venezia , Italy. $7 xx0317382
773    0_
$w MED00007956 $t Hematology $x 1607-8454 $g Roč. 24, č. 1 (2019), s. 337-348
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30757960 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20240516121926 $b ABA008
999    __
$a ok $b bmc $g 1391236 $s 1050231
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 24 $c 1 $d 337-348 $i 1607-8454 $m Hematology $n Hematology $x MED00007956
LZP    __
$a Pubmed-20190405

Find record

Citation metrics

Archiving options